Given that BMCC1 is expressed at low levels in aggressive NB16 and other tumors such as skin, prostate and colon cancers, we propose that inhibition of the expression of BMCC1 may be associated with an increase of drug resistance, resulting in tumor progression. Here, PRUNE2 is linked to colonic neoplasm.